Search Results
Jul 16, 2026, 13:04 ET Vertriebsvereinbarung für Zemcelpro® in Argentinien, Hongkong und Singapur bekannt gegeben
Stoffwechselfunktion wurde konzipiert, um eine höhere Dosis funktioneller therapeutischer Stammzellen bereitzustellen, indem hämatopoetische Stammzellen (HSCs) aus beliebigen Quellen vermehrt und den Auswirkungen von durch die Kultivierung oder Genbearbeitung verursachtem Stress entgegengewirkt wird. ExCellThera
More news about: ExCellThera
Jul 16, 2026, 07:00 ET Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Jul 16, 2026, 07:00 ET Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Jun 11, 2026, 01:06 ET Lizenz- und Liefervereinbarungen für Zemcelpro® (UM171-Zelltherapie) in Kanada bekannt gegeben
metabolischen Fitness ist darauf ausgelegt, eine höhere Dosis funktioneller therapeutischer Stammzellen bereitzustellen, indem sie hämatopoetische Stammzellen (HSCs) aus beliebigen Quellen vermehrt und den Auswirkungen von Stress entgegenwirkt, der durch Kultivierung oder Genbearbeitung verursacht wird. ExCellThera
More news about: ExCellThera
Jun 10, 2026, 07:45 ET Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Jun 10, 2026, 07:45 ET Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Aramchol down-regulates stearoyl CoA desaturase 1 (SCD1) in hepatocytes and in hepatic stellate cells (HSC's) and other tissues including various cancers. Metabolic-dysfunction associated steatohepatitis (MASH) (previously called non-alcoholic steatohepatitis
More news about: Galmed Pharmaceuticals Ltd.
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Research Hospital, continues to enroll patients. The study is a multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ HSCs for gene therapies for patients with SCD (NCT06442761).APHEXDA Performance UpdateFor the full-year 2025, APHEXDA
More news about: BioLineRx Ltd.
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Feb 26, 2026, 08:00 ET Orsini Now Distributing Gene Therapies LYFGENIA™, ZYNTEGLO™, SKYSONA™
eligible patients with early, active cerebral adrenoleukodystrophy (CALD), in which functional copies of the ABCD1 cDNA are added into a patients' own HSCs. This addition results in the production of functional adrenoleukodystrophy protein (ALDP) which can then participate in the local degradation of very
More news about: Orsini
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) erhält NUB-Status 1 in Deutschland
metabolischen Fitness zielt darauf ab, eine höhere Dosis funktioneller therapeutischer Stammzellen bereitzustellen, indem hämatopoetische Stammzellen (HSCs) aus verschiedenen Quellen expandiert und die durch Kultur oder Geneditierung induzierten Stresswirkungen reduziert werden.ExCellThera arbeitet
More news about: ExCellThera
Jan 13, 2026, 11:34 ET Study Reveals Method to Restore 'Exhausted' Blood Stem Cells
stem cells can be restored."The Problem: Stem Cell Stress and Long-Term RisksBlood stem cells, known as hematopoietic stem cells (HSCs), are the body's source for all blood and immune cells. For people with leukemia and other immune diseases, stem cell transplants have served as powerful,
More news about: Cincinnati Children's Hospital Medical Center
Jan 06, 2026, 12:03 ET Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
therapies that reduce liver fat without directly inhibiting the hepatic stellate cells (HSCs) responsible for fibrosis, EVT0185 acts within the liver to directly reprogram fundamental metabolic pathways in both HSCs and hepatocytes, targeting the shared drivers of MASH fibrosis and metabolic dysfunction.
More news about: Espervita Therapeutics, Inc.
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
and in combination with natalizumab are encouraging given that hematopoietic stem cell-based gene therapy for sickle cell disease requires sufficient HSCs (16.5-20x106 CD34+ cells/kg) to generate a product.In two subjects with prior plerixafor mobilization, motixafortide alone, and
More news about: BioLineRx Ltd.
Nov 19, 2025, 10:10 ET Cell Culture Media Market Outlook: Strong 13.2% CAGR to Drive $12.8 Billion Revenue by 2033 - Grand View Research, Inc.
Media Mesenchymal Stem Cells (MSCs) Hematopoietic Stem Cells (HSCs) Induced Pluripotent Stem Cells (iPSCs) Other Stem Cells
More news about: Grand View Research, Inc.
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
low HSC counts in cord blood with our proprietary HSC expansion technology, enabling us to provide HSCs with the best HLA type for the patient. CLD-001, the HLA best-matched and bone marrow-engrafting HSCs, is expected to significantly improve overall survival after HSC therapy.
More news about: Celaid Therapeutics Inc.
Sep 16, 2025, 09:00 ET Air Premia Signs Long-Term Component Support Agreement with Lufthansa Technik for Boeing 787-9 Fleet
it operates long-haul routes that low-cost carriers (LCCs) typically do not cover, all while maintaining a competitive edge in pricing compared to HSCs. This aligns well with the current trend of "value-for-money travel". More information: https://www.airpremia.com/kr/en
More news about: Air Premia